AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.250

0.000

Volume:1.65M

Turnover:415.53K

Market Cap:151.71M

PE:-1.64

High:0.260

Open:0.250

Low:0.245

Close:0.250

52wk High:0.470

52wk Low:0.135

Shares:606.85M

Float Shares:353.07M

Volume Ratio:0.41

T/O Rate:0.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.152

EPS(LYR):-0.152

ROE:-456.96%

ROA:-138.75%

PB:43.71

PE(LYR):-1.64

Loading ...

Overview Company News Filings

Paradigm Biopharmaceuticals Names Chief Medical Officer

MT Newswires Live

Paradigm Biopharmaceuticals Ltd-DR Daniel Furtner Appointed Chief Medical Officer

THOMSON REUTERS

Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13%

MT Newswires Live

PAR Technology Launches Platform to Connect Restaurant Guest Data

MT Newswires Live

Paradigm Biopharmaceuticals - FY Net Loss Attributable A$56.3 Mln

THOMSON REUTERS

Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation

MT Newswires Live

Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook

Simply Wall St.

Exploring 3 Undervalued Small Caps With Insider Buying Across Regions

Simply Wall St.

Paradigm Biopharmaceuticals Completes Drawdown of $3 Million Tranche Under Convertible Note Facility

MT Newswires Live

Paradigm Biopharmaceuticals Completes Enrollment in Knee Osteoarthritis Trial; Shares Gain 7%

MT Newswires Live

Paradigm Biopharmaceuticals Ltd-Results of Share Purchase Plan

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd-Variation to Convertible Securities Agreement

THOMSON REUTERS

Paradigm Biopharmaceuticals Ltd-Share Purchase Plan - Offer Booklet

THOMSON REUTERS

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

MT Newswires Live

BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement

BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement

Paradigm Biopharmaceuticals - Placement at an Issue Price of a$0.19 per Share

THOMSON REUTERS

Paradigm Biopharmaceuticals - Completes a$14.0 Mln Placement

THOMSON REUTERS

BRIEF-Paradigm Biopharmaceuticals Requests Trading Halt

Paradigm Biopharmaceuticals Ltd - Requests Trading Halt Pending Capital Raising Announcement

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/PAR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.25,"timestamp":1789539120000,"preClose":0.25,"halted":0,"volume":1647165,"delay":0,"changeRate":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":606848701,"eps":-0.152232,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-16 16:12:00 AEST","open":0.25,"high":0.26,"low":0.245,"amount":415532,"amplitude":0.06,"askPrice":0.255,"askSize":11500,"bidPrice":0.245,"bidSize":124490,"shortable":3,"etf":0,"ttmEps":-0.152232,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.25,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.414189,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PAR.AU","preClose":0.25,"auctionPrice":0.25,"auctionVolume":72742,"auction":3,"marketStatus":"盘后竞价","timestamp":1789539007103}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-138.75%","roe":"-456.96%","lyrEps":-0.152232,"volumeRatio":0.414189,"shares":606848701,"dividePrice":0,"high":0.26,"amplitude":0.06,"preClose":0.25,"low":0.245,"week52Low":0.135,"pbRate":"43.71","psRate":"17954.10","week52High":0.47,"institutionHeld":0,"latestPrice":0.25,"committee":0.83087,"eps":-0.152232,"divideRate":0,"volume":1647165,"delay":0,"ttmEps":-0.152232,"open":0.25,"prevYearClose":0.34,"prevWeekClose":0.24,"prevMonthClose":0.225,"prevQuarterClose":0.165,"fiveDayClose":0.27,"twentyDayClose":0.17,"sixtyDayClose":0.17,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667947016","title":"Paradigm Biopharmaceuticals Names Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667947016","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667947016?lang=en_us&edition=fundamental","pubTime":"2026-09-15 08:39","pubTimestamp":1789432751,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  appointed Daniel Furtner as its Chief Medical Officer, effective Wednesday, according to a Tuesday Australian bourse filing.Furtner succeeds Donna Skerrett, who will remain with the firm as a senior scientific advisor.Furtner previously served as the senior director of medical affairs for the Asia Pacific region at CSL.Its shares fell 2% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667911446","title":"Paradigm Biopharmaceuticals Ltd-DR Daniel Furtner Appointed Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667911446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667911446?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:47","pubTimestamp":1789429621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUE69ZBXD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666954810","title":"Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666954810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666954810?lang=en_us&edition=fundamental","pubTime":"2026-09-11 11:50","pubTimestamp":1789098623,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  drew down the remaining balance of tranche 4, valued at $2 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Friday Australian bourse filing.Following the drawdown, about $5 million remains available under the facility, providing continued financial flexibility to support phase 3 execution and broader commercial readiness activities, the filing added.The company's shares plunged 13% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664548468","title":"PAR Technology Launches Platform to Connect Restaurant Guest Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2664548468","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664548468?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:17","pubTimestamp":1788268623,"startTime":"0","endTime":"0","summary":"PAR Technology  said Tuesday it has launched a new customer data platform to recognize restaurant guests from their first transaction and unify activity across ordering, payment and other channels.The Guest360 platform works alongside PAR Punchh to create unified guest profiles from in-store, digital and loyalty activity, PAR Technology said.The platform can use the profiles to create dynamic audiences that update automatically based on real spend, visit frequency, menu preference for personalized offers and loyalty milestones, it said.PAR Technology shares were 2% lower in Tuesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","PAR","BK4023","BK4209","QSR","BK4157","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662911058","title":"Paradigm Biopharmaceuticals - FY Net Loss Attributable A$56.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662911058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662911058?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:49","pubTimestamp":1787885347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659184174","title":"Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2659184174","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659184174?lang=en_us&edition=fundamental","pubTime":"2026-08-13 09:25","pubTimestamp":1786584355,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said an independent Data Safety Monitoring Board recommended that the company's phase 3 clinical trial of a knee osteoarthritis treatment continue without modification, according to a Thursday filing with the Australian bourse.The trial is evaluating injectable pentosan polysulfate sodium in participants with knee osteoarthritis, with the change in pain intensity at day 112 set as the primary endpoint.The safety board issued the recommendation after completing a review of about 80% of the participants who have completed dosing, the company said.The trial's interim analysis remains on track for September.Paradigm Biopharmaceuticals shares gained 1% in recent Thursday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651906","title":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651906","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651906?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:36","pubTimestamp":1785904609,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-limiteds-asxpar-profit-outlook","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-limiteds-asxpar-profit-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4157","PAR.AU","BK7067","BK4023","BK7508","PAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654464009","title":"Exploring 3 Undervalued Small Caps With Insider Buying Across Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2654464009","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654464009?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:09","pubTimestamp":1785236980,"startTime":"0","endTime":"0","summary":"In the last week, the United States market has been flat, but over the past 12 months, it has experienced a 15% rise with earnings forecasted to grow by 17% annually. In this environment, identifying stocks that are potentially undervalued with insider buying can be a strategic approach for investors looking to capitalize on growth opportunities within small-cap companies.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/exploring-3-undervalued-small-caps-with-insider-buying-acros-16","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/exploring-3-undervalued-small-caps-with-insider-buying-acros-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4120","ONT","BK4588","FRST","LU1880398554.USD","ONT.AU","BK7067","PAR.AU","BK4211","BK7508","LU1883839398.USD","BK4585","BK4157","RF","PAR","BK4023","LU1880398471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651160090","title":"Paradigm Biopharmaceuticals Completes Drawdown of $3 Million Tranche Under Convertible Note Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2651160090","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651160090?lang=en_us&edition=fundamental","pubTime":"2026-07-13 12:00","pubTimestamp":1783915254,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  completed the drawdown of the fourth tranche, valued at $3 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Monday Australian bourse filing.The drawdown provides additional working capital to support its global phase three clinical trial, evaluating the use of injectable pentosan polysulfate sodium to treat knee osteoarthritis. It completed participant enrolment into the study, with 538 participants randomized.After the drawdown, around $7 million remains available under the facility.Its shares rose 2% in recent trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643022728","title":"Paradigm Biopharmaceuticals Completes Enrollment in Knee Osteoarthritis Trial; Shares Gain 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643022728","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643022728?lang=en_us&edition=fundamental","pubTime":"2026-06-15 14:19","pubTimestamp":1781504346,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  completed enrollment in a phase 3 clinical trial to evaluate its Zilosul injectable pentosan polysulfate sodium for the treatment of pain linked to knee osteoarthritis, according to a Monday filing with the Australian bourse.The company said 538 participants have started treatment in the study, surpassing the original target of 466 participants.An interim analysis of the trial remains on track for September, while top-line results are due in the first quarter of 2027, the company said.Paradigm Biopharmaceuticals shares gained 7% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640819499","title":"Paradigm Biopharmaceuticals Ltd-Results of Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640819499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640819499?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:34","pubTimestamp":1780274056,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUEBW2BFG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507203","title":"Paradigm Biopharmaceuticals Ltd-Variation to Convertible Securities Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631507203?lang=en_us&edition=fundamental","pubTime":"2026-04-30 15:03","pubTimestamp":1777532615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUE8WY1XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631570654","title":"Paradigm Biopharmaceuticals Ltd-Share Purchase Plan - Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2631570654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631570654?lang=en_us&edition=fundamental","pubTime":"2026-04-30 11:19","pubTimestamp":1777519174,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUE7KFXRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630351973","title":"Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2630351973","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630351973?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:57","pubTimestamp":1777265829,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630355391","title":"BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630355391","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630355391?lang=en_us&edition=fundamental","pubTime":"2026-04-27 10:35","pubTimestamp":1777257305,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Paradigm Biopharmaceuticals slips on discounted placement** Paradigm Biopharmaceuticals PAR.AX slips as much as 17.8% to A$0.185, lowest since September 26, 2024** Drug developer anno","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL6N41A05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630035854","title":"BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630035854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630035854?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:36","pubTimestamp":1777253761,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Says Co Completes A$14 Mln PlacementApril 27 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:COMPLETES A$14.0 MILLION PLACEMENTPLACEMENT AT AN ISSUE PRICE OF A$0.19 PER SHAREFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630733225","title":"Paradigm Biopharmaceuticals - Placement at an Issue Price of a$0.19 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2630733225","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630733225?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332250","title":"Paradigm Biopharmaceuticals - Completes a$14.0 Mln Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332250","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630332250?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418069:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079621","title":"BRIEF-Paradigm Biopharmaceuticals Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079621?lang=en_us&edition=fundamental","pubTime":"2026-04-23 06:49","pubTimestamp":1776898157,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Requests Trading HaltApril 23 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:REQUESTS TRADING HALT PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079644","title":"Paradigm Biopharmaceuticals Ltd - Requests Trading Halt Pending Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079644?lang=en_us&edition=fundamental","pubTime":"2026-04-23 06:48","pubTimestamp":1776898134,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN4151C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}